Labcorp announced the introduction of its combined oncology platform, according to a news release.
Labcorp’s oncology test menu includes OmniSeq INSIGHT—a pan-cancer, tissue-based sequencing test for patients with late-stage solid tumor cancers. The test helps physicians make decisions about therapeutic treatments and identify patients who may be eligible for any of several thousand ongoing clinical trials.
The test menu also includes the IntelliGEN Myeloid and liquid biopsy testing for lung cancer. IntelliGEN Myeloid is a next-generation sequencing (NGS) assay that evaluates 50 genes known to be useful in providing diagnostic, prognostic, and predictive information for patients with myeloid malignancies. Meanwhile, liquid biopsy testing examines a blood sample for cancer cells, or pieces of DNA from a tumor circulating in the blood, in order to identify mutations and help select the most effective, targeted treatments. It is a non-invasive testing option in cases where obtaining a tissue sample may be difficult or risky.
